Background: Empiric dosing of gentamicin has not been evaluated in critically ill neonates with unrepaired congenital heart disease (CHD). Many factors may alter gentamicin pharmacokinetics in ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

The data showed that the earlier the concentration was drawn, the more likely it was to result in an incorrect dosing interval according to the nomogram. The data from hours 6-12 that were ...

0.24 mg/kg/week or once-daily somatropin 0.050 mg/kg/day. Children born SGA were randomized to receive either somapacitan 0.24 mg/kg/week, a low dose of somatropin 0.035 mg/kg/day, or a high dose ...

A first-in-human study of an investigational once-daily oral treatment for obesity ... No adverse or serious adverse events were reported in any dosage group. During the 10 days following ...

had similar clinical outcomes and safety profile to once-daily Norditropin ® (somatropin) in children born small for gestational age (SGA) 1, or with Noonan syndrome (NS) 2, or with idiopathic ...

A first-in-human study of an investigational once-daily oral treatment for obesity ... No adverse or serious adverse events were reported in any dosage group. During the 10 days following ...

A first-in-human study of an investigational once-daily oral treatment for obesity ... No adverse or serious adverse events were reported in any dosage group. During the 10 days following ...

Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025.

After 30 days, your doctor will increase your dosage to 7 mg taken once daily. While taking formulation R1, your doctor will carefully monitor your blood sugar level. Depending on how your blood ...